导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 4.76% | 1336/4765 |
| 近一周 | -0.73% | 1226/5455 |
| 近一月 | -7.60% | 4591/5411 |
| 近一季 | -18.22% | 4703/5221 |
| 近半年 | -0.37% | 1460/4910 |
| 近一年 | 8.97% | 1248/4390 |
| 近两年 | 116.97% | 452/2953 |
| 近三年 | 69.83% | 354/2252 |
| 成立以来 | 284.09% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.28% 1748/4961 |
36.21% 899/5312 |
- - |
- - |
| 2025 | 49.81% 476/4813 |
-1.29% 2625/3635 |
3.39% 1024/4076 |
47.16% 482/4524 |
-0.26% 2443/4813 |
| 2024 | 14.77% 1006/3463 |
-4.43% 1667/2808 |
-5.41% 1717/3014 |
27.61% 214/3129 |
-0.51% 1450/3463 |
| 2023 | -20.35% 1874/2656 |
- 1768/2280 |
-6.47% 1649/2385 |
-9.56% 1852/2515 |
-5.84% 1523/2655 |
| 2022 | -27.75% 1504/2207 |
-18.40% 1332/1919 |
6.15% 762/2016 |
-16.78% 1499/2113 |
0.24% 1522/2208 |
| 2021 | 8.86% 468/1822 |
-8.32% 1082/1255 |
26.32% 74/1330 |
-6.45% 931/1466 |
0.47% 1104/1822 |
| 2020 | 64.56% 97/1250 |
3.34% 122/1028 |
29.51% 72/1067 |
6.10% 873/1164 |
15.88% 187/1184 |
| 2019 | 42.46% 213/1092 |
33.11% 144/754 |
-9.48% 658/804 |
7.35% 93/850 |
10.14% 159/918 |
| 2018 | -25.34% 347/834 |
- - |
- - |
- - |
-10.56% 204/691 |
| 2017 | -15.60% 564/714 |
- - |
- - |
- - |
- - |
| 2016 | -26.02% 486/605 |
- - |
- - |
- - |
- - |
| 2015 | 70.22% 3/575 |
- - |
- - |
- - |
- - |
| 2014 | 7.80% 217/237 |
- - |
- - |
- - |
- - |
| 2013 | 75.85% 2/186 |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 融通创业板指数A VS. 长安沪深300非周期A(740101) |